Rallybio Corp (NASDAQ: RLYB) Chief Financial Officer Jonathan I. Lieber reported the disposition of 789 shares of common stock on February 23, 2026, at a per-share price of $5.06, resulting in proceeds of $3,992. According to regulatory filings, the sale was executed to cover tax obligations that arose after previously vested shares.
Since that transaction, Rallybio's shares have climbed roughly 27% over the past week and are trading at $5.50. The Form 4 filed with the Securities and Exchange Commission records the sale and specifies the tax-related purpose that prompted the disposition.
The filings also show that on February 18, 2026, Lieber acquired 2,500 shares of Rallybio with a reported value of $0. Following the February transactions, Lieber's direct holdings in the company total 4,115 shares.
Balance sheet and valuation notes
Publicly available InvestingPro data cited in company documents indicates Rallybio is a micro-cap biotechnology company that currently has more cash than debt on its balance sheet. InvestingPro's Fair Value analysis, also referenced in filings, suggests that RLYB is undervalued at prevailing market levels. The company is included in InvestingPro's coverage universe, which features Pro Research Reports across more than 1,400 U.S. equities for subscribers seeking additional analysis.
Clinical progress and corporate actions
Rallybio announced positive data from a Phase 1 clinical trial of RLYB116, its subcutaneous C5 inhibitor candidate intended for complement-mediated diseases. In the study of healthy volunteers, a 300 mg dose produced complete and sustained inhibition of terminal complement. The company reported the safety profile observed in the trial was similar to that seen with other subcutaneous biologic therapies.
Separately, Rallybio implemented a one-for-eight reverse stock split of its common stock, effective February 6, 2026. Shareholders approved the action, which the company says is designed to increase the per-share trading price and thereby comply with the Nasdaq Capital Market's minimum price requirement for continued listing. The reverse split became effective at 12:01 a.m. Eastern Time, and Rallybio's common stock continues to trade under the same ticker symbol on a split-adjusted basis.
Taken together, the insider transaction, the Phase 1 readout, and the reverse stock split are the primary items disclosed in recent filings. The regulatory filing specifies the reason for the CFO's sale and records his subsequent holdings, while corporate announcements detail clinical results and the board-approved market-structure change.
Summary
The company's CFO sold a small block of shares to satisfy tax obligations linked to vested stock, a transaction recorded on a Form 4. Rallybio also reported promising Phase 1 pharmacodynamic results for RLYB116 in healthy volunteers, and it completed a one-for-eight reverse split to address Nasdaq listing requirements. InvestingPro data cited in filings notes a net cash position versus debt and an indicated undervaluation by Fair Value metrics.
Key points
- Insider sale: CFO Jonathan I. Lieber sold 789 shares on February 23, 2026, at $5.06 per share to cover taxes from vested shares and now holds 4,115 shares directly.
- Clinical milestone: Phase 1 results for RLYB116 showed complete and sustained terminal complement inhibition at a 300 mg dose in healthy volunteers, with a safety profile comparable to other subcutaneous biologics.
- Market mechanics: A one-for-eight reverse stock split took effect February 6, 2026, to raise the per-share price and comply with Nasdaq Capital Market minimum listing standards.
Risks and uncertainties
- Listing compliance: The company implemented a reverse stock split specifically to address Nasdaq's minimum price requirement, indicating an ongoing need to meet exchange standards.
- Early-stage data: The Phase 1 trial results reported were from healthy volunteers and reflect pharmacodynamic and safety observations at an early clinical stage.
- Insider disposition context: The Form 4 filing states the CFO's sale was to cover tax obligations after vesting; the filing does not provide further detail beyond that stated purpose.